alexa Computational Shotgun Drug Repurposing For Myriad Diseases
ISSN: 0974-276X

Journal of Proteomics & Bioinformatics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Proteomics & Bioinformatics
August 04-06, 2014 Hilton-Chicago/Northbrook, Chicago, USA

Geetika Sethi, Gaurav Chopra, George White, Mark Minie, Jeremy Horst and Ram Samudrala
ScientificTracks Abstracts: J Proteomics Bioinform
DOI: 10.4172/0974-276X.S1.071
The goal of this study is to predict the drug behavior based on compound-proteome interaction signatures and generate high-value drug prioritizations from ranking indication-specific interaction signatures. We had previously developed a platform based on computational analysis of novel drug opportunities (CANDO) that can simultaneously predict the interactions of indication-specific drugs with a library of protein targets to generate a binary matrix of interaction signatures (?all? drugs ? ?all? protein structures ? ?all? indications), in effect inferring homology of drug behavior at a proteomic level. In the current study, a binary matrix of 180 million predicted interaction signatures (approx.) between 3,733 human ingestible compounds (FDA approved drugs and supplements) and 48278 proteins (universal proteome set) were first compared with each other and then ranked in an indication specific manner. We have developed a ?hold one out? compound-centric benchmarking algorithm for 1439 disease indications (FDA and NLM), where there are at least two approved compounds so that one compound could be used as a test to fish for the other compound with the same indication. Compounds are ranked using the compound-proteome signature comparison approach and the accuracy is measured by whether related compounds are seen in the top 1% (37) of the rankings. This is contrasted to the results from best performing randomly generated matrix (out of 16) which is created by swapping the rows and columns randomly (so composition/distribution of interactions is the same). We analyzed the percentage accuracy of identifying compounds with the same indication within the top 1% (37) compounds or in other words, the likelihood that any given prediction of a compound will be effective as a drug for a particular indication. The top compounds produced by this integrated rankings method are considered to be putative repurposed drugs for their respective indications. For a total of 13746 compound-disease pairs, the average ranking for top 1% is 24.9%. Out of 1439, 654 disease indications showed a non-zero output for top 1% with an average of 33.1%. To conclude, we have developed a drug repurposing platform that considers compound-proteome interaction signatures to predict drug behavior and uncovers potential drug candidates that can be repurposed for multiple indications.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version